Health score, price, valuation, risk signals, and key metrics at a glance.
SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and Singapore. The company offers advertising and marketing services across social media networks; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals; leasehold improvement services; and design services for clinics, medical equipment, and medical consumables procurement. It also provides loyalty program management, labor and function supporting, and management consulting services; and IT software solutions, as well as engages in franchising activities; and distributes medical equipment and devices, implants, injection materials, other medical consumables, skin care and beauty products, and cosmetic products to franchisee clinics for resale to clinic customers. In addition, the company offers surgical and non-surgical surgeries that include breast augmentation; liposuction; rejuvenation treatments, such as treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging; laser skin toning and spot removal; eyes double fold surgery; rhinoplasty; treatment of osmidrosis and hyperhidrosis; hair transplants; gynecological formation treatments; laser hair removal; face line surgeries; cosmetical dental procedures; tattoo removal; lasik eye surgery; lateral canthoplasty; brow lift procedures; androgenetic alopecia treatment; and cheek sagging prevention methods. Further, it owns and operates treatment centers under the SBC brand. SBC Medical Group Holdings Incorporated was founded in 2000 and is headquartered in Irvine, California.
Strongest: Balance Sheet & Red Flags (20/25); weakest: Growth (1/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently near its 8-quarter median.
Currently near its 8-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.
Debt-to-equity has risen 392.9% recently — increasing financial risk even if the current ratio is manageable.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
Currently near its 9-quarter median.
Revenue has softened, declining in 3 quarters. Watch for further erosion.
FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.
Shares outstanding increased 7.9% — significant dilution, likely from stock compensation or capital raises.
